Camber Pharmaceuticals, Inc. announced the approval of its Abbreviated New Drug Application for lisdexamphetamine dimesylate, a strategic development that enters the generic market for this treatment. This move creates immediate competitive pricing pressure on existing brands but may encourage expansion within this niche due to continued legacy demand.